Hollie Franklin, Author at Drugs in Context

Drugs for paediatric hyperinflammatory syndromes

Kam Lun Hon, Alexander KC Leung, Wing Hang Leung, Karen Ka Yan Leung, Kai Ning Cheong, Pamela PW Lee

Article Type

Review

Published

27 May 2022

This paper provides an updated narrative review on the pathophysiology, manifestations and management approaches for common hyperinflammatory syndromes.

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Susana Puig, Carlos Serra-Guillén, Gemma Pérez-Pastor, Álvaro Martínez-Domenech, Ricardo Fernández-de-Misa Cabrera

Article Type

Case Series

Published

23 May 2022

Xeroderma pigmentosum: an updated review

Alexander KC Leung, Benjamin Barankin, Joseph M Lam, Kin Fon Leong, Kam Lun Hon

Article Type

Review

Published

25 Apr 2022

This narrative review aims to familiarize physicians with the clinical features, diagnosis and management of xeroderma pigmentosum.

Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome

Steven H Abman, Nicholas R Fox, M Ibrahim Malik, Sneha S Kelkar, Shelby L Corman, Sanika Rege, Jenna Bhaloo, Rachel Shah, Ren-Jay Shei, Dana Saporito, Nisreen Shamseddine, Erik DeBoer, George J Wan, on behalf of the NOTICE Study Investigators

Article Type

Original Research

Published

11 Apr 2022

This article aims to describe real-world inhaled nitric oxide use and outcomes in patients with COVID-19 with mild-to-moderate acute respiratory distress syndrome in the United States.

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease – where we are and where we are going

Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

Article Type

Review

Published

11 Apr 2022

This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.